Deeper insight into chronic kidney disease-related atherosclerosis: Comparative proteomic studies of blood plasma using 2DE and mass spectrometry

Journal of Translational Medicine

Volumn 13, Issue 1, 2015, Pages

  Luczak, Magdalena ^a,c   Formanowicz, Dorota ^b   Marczak, Łukasz ^a   Pawliczak, Elzbieta ^b   Wanic Kossowska, Maria ^b   Figlerowicz, Marek ^a,c   Stobiecki, Maciej ^a  

^a INSTITUTE OF BIOORGANIC CHEMISTRY   (Poland)

^b POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^c POZNAN UNIVERSITY OF TECHNOLOGY   (Poland)

Author keywords

Atherosclerosis; Cardiovascular disease; Chronic kidney disease; Mass spectrometry; Proteome profiling

Indexed keywords

ALPHA 1 MICROGLOBULIN; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN B; APOLIPOPROTEIN B100; COMPLEMENT FACTOR 4A13; COMPLEMENT FACTOR C4B; FIBRINOGEN GAMMA; HAPTOGLOBIN; INTER ALPHA TRYPSIN INHIBITOR H4; KININOGEN; PLASMA PROTEIN; PREALBUMIN; UNCLASSIFIED DRUG;

ADULT; AFFINITY CHROMATOGRAPHY; ARTICLE; ATHEROSCLEROSIS; BIOINFORMATICS; CHRONIC KIDNEY DISEASE; CONTROLLED STUDY; FEMALE; GENE ONTOLOGY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; PLASMA; PROTEIN ANALYSIS; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SELECTED REACTION MONITORING; TANDEM MASS SPECTROMETRY; TWO DIMENSIONAL GEL ELECTROPHORESIS; BIOLOGY; BLOOD; CHRONIC KIDNEY FAILURE; COMPARATIVE STUDY; COMPLICATION; DEMOGRAPHY; METABOLISM; MIDDLE AGED; MOLECULAR WEIGHT; PRINCIPAL COMPONENT ANALYSIS; PROCEDURES; PROTEOMICS; REPRODUCIBILITY;

ATHEROSCLEROSIS; BLOOD PROTEINS; COMPUTATIONAL BIOLOGY; DEMOGRAPHY; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; MALE; MIDDLE AGED; MOLECULAR WEIGHT; PRINCIPAL COMPONENT ANALYSIS; PROTEIN INTERACTION MAPS; PROTEOMICS; RENAL INSUFFICIENCY, CHRONIC; REPRODUCIBILITY OF RESULTS; TANDEM MASS SPECTROMETRY;

EID: 84938602536     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/s12967-014-0378-8     Document Type: Article

References (50)

1. Eckardt K-U, Coresh J, Devuyst O, Johnson RJ, Köttgen A, Levey AS, et al. Evolving importance of kidney disease: from subspecialty to global health burden. Lancet. 2013;382:158-69.
2. National Kidney Foundation (NKF) Kidney Disease Outcome Quality Initiative (K/DOQI). Advisory board. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Kidney disease outcome quality initiative. Am J Kidney Dis. 2002;39:S1-S246.
3. Briasoulis A, Bakris GL. Chronic kidney disease as a coronary artery disease risk equivalent. Curr Cardiol Rep. 2013;3:340.
4. Weiner DE, Tighiouart H, Amin MG, Stark PC, MacLeod B, Griffith JL, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community based studies. J Am Soc Nephrol. 2004;15:1307-15.
5. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, et al. Relation between renal dysfunction and cardiovascular outcomes after myocardial infarction. N Engl J Med. 2004;351:1285-95.
6. Anderson TJ, Grégoire J, Hegele RA, Couture P, Mancini GB, McPherson R, et al. 2012 update of the canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013;2:151-67.
7. Kalantar-Zadeh K, Block G, Humphreys MH, Kopple JD. Reverse epidemiology of cardiovascular risk factors in maintenance dialysis patients. Kidney Int. 2003;63:793-808.
8. Kalantar-Zadeh K, Block G, Horwich T, Fonarow GC. Reverse epidemiology of conventional cardiovascular risk factors in patients with chronic heart failure. J Am Coll Cardiol. 2004;43:1439-44.
9. Luczak M, Formanowicz D, Pawliczak E, Wanic-Kossowska M, Wykretowicz A, Figlerowicz M. Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. Proteome Sci. 2011;9:25.
10. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann Intern Med. 1999;130:461-70.
11. Luczak M, Kaźmierczak M, Handschuh L, Lewandowski K, Komarnicki M, Figlerowicz M. Comparative proteome analysis of acute myeloid leukemia with and without maturation. J Proteomics. 2012;75:5734-48.
12. Candiano G, Bruschi M, Musante L, Santucci L, Ghiggeri GM, Carnemolla B, et al. Blue Silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis. 2004;25:1327-33.
13. Szklarczyk D, Franceschini A, Kuhn M, Simonovic M, Roth A, Minguez P, et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 2010;39:D561-8.
14. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, Cherry JM, et al. Gene ontology: tool for the unification of biology. The gene ontology consortium. Nat Genet. 2000;25:25-9.
15. Mi H, Muruganujan A, Casagrande JT, Thomas PD. Large-scale gene function analysis with the PANTHER classification system. Nature Protocols. 2013;8:1551-66.
16. Luczak M, Marczak L, Stobiecki M. Optimization of plasma sample pretreatment for quantitative analysis using iTRAQ labeling and LC-MALDI-TOF/TOF. PLoS One. 2014;9:e101694.
17. Akerström B, Lögdberg L, Berggard T, Osmark P, Lindqvist A. Alpha(1)-Microglobulin: a yellow-brown lipocalin. Biochim Biophys Acta. 2000;1482:172-84.
18. Penders J, Delanghe JR. Alpha 1-microglobulin: clinical laboratory aspects and applications. Clin Chim Acta. 2004;346:107-18.
19. Gundry RL, Fu Q, Jelinek CA, Van Eyk JE, Cotter RJ. Investigation of an albumin-enriched fraction of human serum and its albuminome. Proteomics Clin Appl. 2007;1:73-88.
20. Yadav AK, Bhardwaj G, Basak T, Kumar D, Ahmad S, Priyadarshini R, et al. A systematic analysis of eluted fraction of plasma post immunoaffinity depletion: implications in biomarker discovery. PLoS One. 2011;6:e24442.
21. Stempfer R, Kubicek M, Lang IM, Christa N, Gerner C. Quantitative assessment of human serum high-abundance protein depletion. Electrophoresis. 2008;29:4316-23.
22. Tu C, Rudnick PA, Martinez MY, Cheek KL, Stein SE, Slebos RJ, et al. Depletion of abundant plasma proteins and limitations of plasma proteomics. J Proteome Res. 2010;9:4982-91.
23. Leung LL. Interaction of histidine-rich glycoprotein with fibrinogen and fibrin. Clin Invest. 1986;77:1305-11.
24. Tissot JD, Schifferli JA, Hochstrasser DF, Pasquali C, Spertini F, Clement F, et al. Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide. J Immunol Methods. 1994;173:63-75.
25. Jenne DE, Lowin B, Peitsch MC, Bottcher A, Schmitz G, Tschopp JJ. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. Biol Chem. 1991;266:11030-6.
26. Kato GJ. Haptoglobin halts hemoglobin's havoc. J Clin Invest. 2009;119:2140-2.
27. Song J, Patel M, Rosenzweig CN, Chan-Li Y, Sokoll LJ, Fung ET, et al. Quantification of fragments of human serum inter-alpha-trypsin inhibitor heavy chain 4 by a surface-enhanced laser desorption/ionization-based immunoassay. Clin Chem. 2006;52:1045-553.
28. Hertle E, Stehouwer CD, van Greevenbroek MM. The complement system in human cardiometabolic disease. Mol Immunol. 2014;61:135-48.
29. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-95.
30. Oksjoki R, Kovanen PT, Pentikäinen MO. Role of complement activation in atherosclerosis. Curr Opin Lipidol. 2003;14:477-82.
31. Yasojima K, Schwab C, McGeer EG, McGeer PL. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am J Pathol. 2001;158:1039-51.
32. Marcovina S, Packard CJ. Measurement and meaning of apoli-poprotein AI and apolipoprotein B plasma levels. J Intern Med. 2006;259:437-46.
33. Shilpasree AS, Sahukar S, Murthy J, Kumar K. A study of serum apoplipoprotein A1, apolipoprotein B and lipid profile in stroke. J Clin Diagn Res. 2013;7:1303-6.
34. Boren J, Ekstrom U, Agren B, Nilsson-Ehle P, Innerarity TL. The molecular mechanism for the genetic disorder familial defective apolipoprotein B100. J Biol Chem. 2001;276:9214-8.
35. Palmer AM, Murphy N, Graham A. Triglyceride-rich lipoproteins inhibit cholesterol efflux to apolipoprotein (apo) A1 from human macrophage foam cells. Atherosclerosis. 2004;173:27-38.
36. Landmesser U. High density lipoprotein - should we raise it? Curr Vasc Pharmacol. 2012;10:718-9.
37. Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, von Eckardstein A, et al. Low apolipoprotein A-IV plasma concentration in men with coronary artery disease. J Am Coll Cardiol. 2000;36:751-7.
38. Koren MJ, Davidson MH, Wilson DJ, Fayyad RS, Zuckerman A, Reed DP. Focused atorvastatin therapy in managed-care patients with coronary heart disease and CKD. Am J Kidney Dis. 2009;53:741-50.
39. Shepherd J, Kastelein JJ, Bittner V, Deedwania P, Breazna A, Dobson S, et al. TNT (Treating to New Targets) Investigators: intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol. 2008;51:1448-54.
40. Fellström BC, Jardine AG, Schmieder RE, Holdaas H, Bannister K, Beutler J, et al. AURORA Study Group: rosuvastatin and cardiovascular events in patients undergoing hemodialysis. N Engl J Med. 2009;360:1395-407.
41. Wanner C, Krane V, Marz W, Olschewski M, Mann JF, Ruf G, et al. German Diabetes and Dialysis Study Investigators: atorvastatinin patients with type 2 diabetes mellitus undergoing hemodialysis. N Engl J Med. 2005;353:238-348.
42. Strippoli GF, Craig JC. Sunset for statins after AURORA? N Engl J Med. 2009;360:1455-77.
43. Kassimatis TI, Konstantinopoulos PA. Rosuvastatin in patients undergoing hemodialysis. N Engl J Med. 2009;361:93.
44. Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Perkovic V, Nigwekar SU, et al. HMG CoA reductase inhibitors (statins) for dialysis patients. Cochrane Database Syst Rev. 2013;9:CD004289.
45. Palmer SC, Craig JC, Navaneethan SD, Tonelli M, Pellegrini F, Strippoli GF. Benefits and harms of statin therapy for persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med. 2012;157:263-75.
46. Baigent C, Landray MJ, Reith C, Emberson J, Wheeler DC, Tomson C, et al. SHARP Investigators: the effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial. Lancet. 2011;377:2181-92.
47. Kassimatis TI, Goldsmith DJA. Statins in chronic kidney disease and kidney transplantation. Pharmacol Res. 2014;88:62-73.
48. Iseki K, Yamazato M, Tozawa M, Takishita S. Hypocholesterolemia is a significant predictor of death in a cohort of chronic hemodialysis patients. Kidney Int. 2002;61:1887-93.
49. Liu Y, Coresh J, Eustace JA, Longenecker JC, Jaar B, Fink NE, et al. Association between cholesterol level and mortality in dialysis patients: role of inflammation and malnutrition. JAMA. 2004;291:451-9.
50. Kilpatrick RD, McAllister CJ, Kovesdy CP, Derose SF, Kopple JD, Kalantar-Zadeh K. Association between serum lipids and survival in hemodialysis patients and impact of race. J Am Soc Nephrol. 2007;18:293-303.